Stryker Faces Analyst Downgrade Amid Wolfe Research Rating Shift

Wolfe Research issued a downgrade of Stryker (NYSE: SYK) this week, marking a notable shift in analyst sentiment in the MedTech space. The firm downgraded Stryker and simultaneously upgraded Abbott Laboratories, signaling a reassessment of growth and risk profiles among large-cap medical device companies. This development comes amid broader analyst activity affecting Stryker’s outlook. According to Investing.com, Wolfe’s rating change was published on August 13, 2026, although it did not specify the precise rating tiers (such as from “Overweight” to “Neutral” or “Underweight”) or provide a new price target.

Additionally, Citizens Research Group recently adjusted its outlook on Stryker as well. On August 3, 2026, Citizens reduced its price target for SYK to $400 from $440 while maintaining a “Market Perform” rating, citing concerns around supply chain disruptions. This adjustment reflects growing caution around Stryker’s operational continuity, despite no formal change in sentiment classification.

These analyst developments arrive on the heels of Stryker’s second-quarter earnings release on July 29, 2026. The company reported adjusted EPS of $3.69, beating consensus by $0.20, alongside reaffirmed full-year guidance. Despite those fundamentals, the recent downgrades suggest analysts are increasingly watching for execution risks amid a complex supply and demand backdrop.

From a market perspective, SYK shares traded at approximately $329.45 as of August 21, 2026, reflecting a +1.05% intraday movement. This price sits below the previous price targets cited by analysts and highlights the gap between investor expectations and broker sentiment.

Looking forward, investors will want to monitor upcoming earnings commentary, supply chain updates, and any incremental analyst revisions. Exposure to robotics and orthopedic segments, including Stryker’s Mako platform, may offer upside if execution stabilizes. However, until the outlook clears, investor caution may persist.